Novo Nordisk
References from this period: 5 LinkedIn recommendations, full text. They vouch for the role, not for any one claim.
Proof points: 14
| Role | Product | Situation | Task | Action | Result | Year | Skills |
|---|---|---|---|---|---|---|---|
| Senior Product Manager at Novo Nordisk | Wegovycare Wegovycare, a digital service to drive retention and repeat prescriptions for Wegovy | The brief was a set of standalone features the business thought would help, but nobody had talked to the patients. | Find the lever that would keep patients on treatment and coming back for repeat prescriptions. | Talked to patients: everyone wanted the same three things, how much weight they will lose, whether this is normal, whether they are on track. Made those the core loop; built a weight-loss prediction model in Excel to answer the first, then a profiling engine to personalise the rest. | 10% penetration in the first national market. Fastest-scaling and biggest-adopted digital product at Novo. | Mar 2020 - Feb 2022 | algorithm, API, regulated, pharma, healthcare, patients, discovery, prototyping, ways of working, growth, retention, roadmap, 0 to 1, marketing, team leadership, stakeholders, consumer |
| Senior Product Manager at Novo Nordisk | Wegovycare Wegovycare weight-loss prediction model | Patient research showed everyone wanted the same three things: how much weight they will lose, whether this is normal, whether they are on track. Nothing in the brief answered them. | Make those three questions the core loop of the product, and find the growth lever inside them. | Built a weight-loss prediction model answering the first question: a predicted trajectory for the individual to check progress against. Started as an Excel spreadsheet on a laptop; the maths worked out with the strongest backend engineer, then taken from concept to prototype. The same check-ins fed the profiling engine. | Patients could see whether they were on track against their own projection. The model was later spun out as a Bayesian API service, a product in its own right, and the team extended it from weight to HbA1c. | Mar 2020 - Feb 2022 | algorithm, API, regulated, pharma, healthcare, patients, discovery, prototyping, ways of working, growth, retention, roadmap, 0 to 1, marketing, team leadership, stakeholders, consumer |
| Senior Product Manager at Novo Nordisk | Wegovycare Wegovycare, a digital service to drive retention and repeat prescriptions for Wegovy | Applied for a SaMD product role at Novo; put forward instead for a digital solution for a then unheard-of weight-loss medicine. The final-round brief was solution-first: standalone features the business thought would help. Nobody had spoken to patients. | Persuade the business to set the brief aside and start with the problem, then use that as a mandate to change how they worked. | First product team at Novo to interview patients, run discovery, build prototypes and co-create with markets. Led a cross-functional team of 10 across the full product lifecycle; it took persuasion and a leap of faith from stakeholders. | Launched on time and on budget. 10% penetration in the first national market, the biggest adoption of any digital solution at Novo; still live. Asked to scale the ways of working across the organisation and promoted to Associate Product Director. | Mar 2020 - Feb 2022 | pharma, healthcare, patients, discovery, prototyping, ways of working, growth, retention, launch, 0 to 1, team leadership, stakeholders, budget |
| Associate Product Director at Novo Nordisk | GenAI proof of concept for automating compliance reviews Agentic RAG proof of concept for compliance reviews, with a Figma plugin | Every release of health software needed sign-off from medical, legal and regulatory reviewers. The process was built for marketing materials, not software: every screen was manually captured as a PDF and reviewed manually, stacking the regulatory risk to the end of the development cycle and sometimes adding months to delivery. | Test whether an LLM could take on the review so product teams could shift left: fail in design, not at review. Two acceptance tests set up front: useful to product teams, and catches what the manual review catches. | Used an internal LLM sandbox to build a RAG model of the guidelines and regulations, producing a full audit trail per submission. Built a prototype agent that plugged into Figma so designers could query the guidelines before investing effort. Pitched it to senior leadership & tested with product team. | Product team loved it. The proof of concept showed a clear path to much faster release cycles, but the timing was 12 months too early & the business was not ready for AI. Tom moved to help the Wegovy Pill launch. | Feb 2022 - Feb 2026 | AI, GenAI, regulated, compliance, pharma, healthcare, discovery, prototyping, ways of working, launch, marketing, team leadership, stakeholders |
| Associate Product Director at Novo Nordisk (contributed, one of a team) | Wegovy Pill launch Wegovy Pill launch, consumer workstream | Pitched for and invited onto the launch team for a company-critical initiative to inject new thinking (very unusual for a digital role). Digital, packaging and direct distribution sat in separate silos, each with its own assumptions. | Lead the HQ consumer workstream. | Applied subscription-model thinking to connect the physical product to digital fulfilment: QR codes on the boxes linking to the digital experience, and work with production on bundling three boxes in a tertiary carton. | Contributed to the largest pharma launch on record. | Feb 2022 - Feb 2026 | pharma, healthcare, patients, growth, retention, launch, marketing, SaaS, team leadership, international, consumer, budget |
| Associate Product Director at Novo Nordisk | CagriSema Digital discovery programme for CagriSema, the company's top drug asset | CagriSema was the first drug to span two therapy areas, diabetes and obesity. Each business unit ran independently with their own priorities and budgets. | Define what digital initiatives should accompany the drug, get both business units to agree, and get it funded. | Started with the problem, and uncovering the new user journeys to create a shared understanding of the problem space across both units. Then ideation: 128 candidate ideas, cut to a shortlist of 5, assumption-tested with prototypes, 4 recommended, each with a funding-gated rollout. Navigated the programme through internal governance. | Funding secured for a portfolio of 4 digital initiatives (a first). Aligned two business units on a common digital strategy (also a first). | Feb 2022 - Feb 2026 | AI, GenAI, regulated, compliance, pharma, healthcare, patients, discovery, prototyping, incubation, ways of working, growth, retention, funnels, experimentation, launch, brand, team leadership, stakeholders, consumer, budget |
| Associate Product Director at Novo Nordisk | Digital Incubation Digital incubation unit for branded digital engagement, evaluating build, buy and partner solutions | Asked after Wegovycare to scale its ways of working across the product organisation: to work across silos and help move the organisation from solution-first project thinking to a product model with an outcomes focus. | Build the unit that shapes the organisation's next big bets, and make problem-first the default. | Built the incubation unit entirely through influence. Designed a portfolio model and a gated incubation pipeline. Wrote the discovery playbook. Coached the incubation PMs. Secured funding and managed resourcing and cross-charges for the incubation teams. Evaluated build, buy and partner options for each bet. | Moved the business from solution-first to problem-first, and from output to outcomes. | Feb 2022 - Feb 2026 | AI, GenAI, regulated, compliance, pharma, healthcare, patients, discovery, incubation, ways of working, growth, retention, funnels, experimentation, launch, brand, team leadership, stakeholders, consumer, budget |
| Associate Product Director at Novo Nordisk | Product Operations standards, artefacts, ways of working | A wider remit across the product pipeline, to complete the move to a product operating model. | Establish metrics across a portfolio of 12 products. | Set product artefacts and quality standards: gate model and deliverables, product-ops metrics, portfolio reports, business case templates, problem and north-star statements. | Helped product teams connect work to commercial outcomes. | Feb 2022 - Feb 2026 | AI, GenAI, regulated, compliance, pharma, healthcare, patients, discovery, incubation, ways of working, growth, retention, funnels, experimentation, launch, brand, team leadership, stakeholders, consumer, budget |
| Associate Product Director at Novo Nordisk | Head of Patient Products Patient Solutions, a portfolio of consumer engagement products (companion apps adjacent to the medicines) | Interim reorg of product teams before the Wegovy Pill project. | Lead 6 experienced PMs building consumer engagement products, managing by outcomes; for a period, before moving into the pill team where the need was greatest. | Individual coaching and weekly experiment sharing; made individual product metrics public. | Broke product silos, established weekly demos and experiment sharing, encouraged learning loops. | Feb 2022 - Feb 2026 | AI, GenAI, regulated, compliance, pharma, healthcare, patients, discovery, incubation, ways of working, growth, retention, funnels, experimentation, launch, brand, team leadership, stakeholders, consumer, budget |
| Associate Product Director at Novo Nordisk | project steercos Chaired project steercos. Flipped the format from status updates to interactive co-creation | Steercos were project management checklists: project not product focused, and unsuited for high-uncertainty discovery-stage products. | Chair project steercos. | Flipped the format from status updates to interactive co-creation. | Cross-functional VPs moved from product sceptics to advocates. | Feb 2022 - Feb 2026 | AI, GenAI, regulated, compliance, pharma, healthcare, patients, discovery, incubation, ways of working, growth, retention, funnels, experimentation, launch, brand, team leadership, stakeholders, consumer, budget |
| Senior Product Manager at Novo Nordisk | Wegovycare Wegovycare profiling and customisation engine, delivered as an interactive magazine | Research showed every patient journey is different and every patient has different needs. A linear app would not work, and the drop-off risks were different for each person. | Identify each patient's drop-off risks and act on them automatically, with a system that coped with real people who do not check in on schedule. | Tom's own idea and pattern, most of the algorithm his. Built a continuous profiling engine combining clinical data, usage signals and PROMs. Applied a consumer marketing playbook to act on the top risk: it decided what content was shown and could trigger a messaging flow. Ran on fuzzy logic, tolerating gaps and misuse. Output to the patient: an interactive magazine that changed with them. | Every patient got a personalised experience from one product and one codebase. Part of the launch that reached 10% adoption in the first market and became the fastest-scaling digital product at Novo. | Mar 2020 - Feb 2022 | algorithm, API, regulated, pharma, healthcare, patients, discovery, prototyping, ways of working, growth, retention, roadmap, launch, 0 to 1, marketing, team leadership, stakeholders, consumer |
| Senior Product Manager at Novo Nordisk | Wegovycare Wegovycare, digital patient platform for obesity medicine, built to scale | Every market needed its own version of every digital product, so nothing at Novo had ever scaled beyond one country. | Build one product that many markets could adopt and adapt without forking it. | Designed for scale: modular architecture, feature flags, an integrated CMS and a translation pipeline. Systematised co-creation with the markets so they shaped the product rather than waiting for it. | Novo's first digital health product adopted by multiple markets. First digital Novo product to scale. | Mar 2020 - Feb 2022 | algorithm, API, regulated, pharma, healthcare, patients, discovery, prototyping, ways of working, growth, retention, roadmap, 0 to 1, marketing, team leadership, stakeholders, consumer |
| Senior Product Manager at Novo Nordisk | Wegovycare releases Wegovycare release process | Release cycles for digital products at Novo were yearly. Every release carried heavy documentation for a high-regulation environment, and the documentation was written by hand. | Release often enough to learn from patients, inside the same regulatory rules. | Automated the documentation and the release workflows so the compliance paperwork fell out of the build rather than being written afterwards. | Release cycles went from yearly to bi-monthly. Fast for pharma. Iterative learning became possible. | Mar 2020 - Feb 2022 | algorithm, API, regulated, compliance, pharma, healthcare, patients, discovery, prototyping, ways of working, growth, retention, roadmap, 0 to 1, marketing, team leadership, stakeholders, consumer |
| Senior Product Manager at Novo Nordisk | Wegovycare roadmap Wegovycare roadmap | A project-model organisation steered by deliverables and dates. Nobody on the product had a way of saying what mattered next, or why. | Own the product vision and the backlog, and steer priorities by what patients did and said rather than by the plan. | Set the vision. Implemented OKRs, as in every product, else how do you know you have succeeded. Owned the backlog end to end: problem statements, user stories, acceptance criteria, sprint-by-sprint prioritisation with a cross-functional team of 10. Steered priorities and the roadmap with qualitative and quantitative signals together, patient interviews beside usage data. | A roadmap that traced back to patient evidence and a definition of success the stakeholders had agreed up front. The product hit 10% adoption in its first market against that definition. | Mar 2020 - Feb 2022 | algorithm, API, regulated, pharma, healthcare, patients, discovery, prototyping, ways of working, growth, retention, roadmap, 0 to 1, marketing, team leadership, stakeholders, consumer |
Tell me about Novo Nordisk
source: Tom's own account
Novo Nordisk is a global pharmaceutical company, best known for its treatments in obesity and diabetes. I worked at Novo for almost 6 years (2020 to 2026).
I joined Novo as a Senior Product Manager, to build a digital patient solution for Wegovy, a then-unheard-of weight loss medicine. I led the full product lifecycle end to end, and it was really a stealth transformation project, where I could bring my learnings from LEO but to in-house transformation.
I was later asked to scale learnings from Wegovycare across the product organisation and was promoted to Associate Product Director. In this role, I had a much wider remit, and worked on high-impact, cross-functional projects across the organisation.
Want to know more? Ask about either of my roles, the transformation work, or specific projects like Wegovy or the GenAI proof of concept.
Direct answers
- Company context: Novo Nordisk is about 70,000 people globally. I worked in the digital health unit, about 100 people; the Wegovycare product team was around 10.
source: Tom's own account, direct answers